@article{a8bde8451db94d0f8e7ea2acafb90eef,
title = "Inhaled triple therapy in chronic obstructive pulmonary disease",
keywords = "Administration, Inhalation, Adrenal Cortex Hormones, Bronchodilator Agents, Drug Therapy, Combination, Humans, Pulmonary Disease, Chronic Obstructive",
author = "Brian Lipworth and Kuo, {Chris Rui Wen} and Sunny Jabbal",
note = "MM reports personal fees from Boehringer Ingelheim, GlaxoSmithKline, and Novartis. POG reports personal fees from AstraZeneca and personal fees and non-financial support from ALK-Abello, Boehringer Ingelheim, Chiesi, and Novartis. NM reports personal fees from Merck, Pfizer, IPSEN, MSD France, Servier, Novartis, and Oxon; and grants from Pierre Fabre, Biogen, Novartis, J&J, Vifor Pharma, Merck-Serono, Sanofi, Bayer, Lundbeck, Merck & Co, Allergan, AstraZeneca, BMS, J&J, Stallergene, and Boehringer Ingelheim, outside the submitted work",
year = "2018",
month = sep,
day = "29",
doi = "10.1016/S0140-6736(18)31795-1",
language = "English",
volume = "392",
pages = "1112--1113",
journal = "Lancet",
issn = "0140-6736",
publisher = "ELSEVIER SCIENCE INC",
number = "10153",
}